Acelyrin
(NASDAQ:SLRN)
$4.08
0.03[0.74%]
At close: May 29
$4.08
0[0.00%]
After Hours: 4:00PM EDT
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Acelyrin Stock (NASDAQ:SLRN), Quotes and News Summary

Acelyrin Stock (NASDAQ: SLRN) stock price, news, charts, stock research, profile.

Open$3.990
Close$4.080
Volume / Avg.2.317M / 1.170M
Day Range3.990 - 4.220
52 Wk Range3.910 - 29.880
Market Cap$404.030M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
32
Short Interest
8.11%
Days to Cover8.14

Recent News

Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half of 2024.
Vandana Singh
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show sustained clinical improvements, with HiSCR75 and HiSCR100 achievements. Phase 3 trial results expected by end of 2024.
Vandana Singh
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Lisa Levin
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
2
Dec 23
2
1
Mar
1
Apr
3
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
2.9
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
SLRN
SKYE

FAQ

Q

How do I buy Acelyrin (SLRN) stock?

A

You can purchase shares of Acelyrin (NASDAQ: SLRN) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Acelyrin's (SLRN) competitors?

A

Other companies in Acelyrin’s space includes: Skye Bioscience (NASDAQ:SKYE), Voyager Therapeutics (NASDAQ:VYGR), Korro Bio (NASDAQ:KRRO), Fate Therapeutics (NASDAQ:FATE) and Anika Therapeutics (NASDAQ:ANIK).

Q

What is the target price for Acelyrin (SLRN) stock?

A

The latest price target for Acelyrin (NASDAQ: SLRN) was reported by HC Wainwright & Co. on Wednesday, May 22, 2024. The analyst firm set a price target for 18.00 expecting SLRN to rise to within 12 months (a possible 341.18% upside). 18 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Acelyrin (SLRN)?

A

The stock price for Acelyrin (NASDAQ: SLRN) is $4.08 last updated May 29, 2024 at 4:00 PM EDT.

Q

Does Acelyrin (SLRN) pay a dividend?

A

There are no upcoming dividends for Acelyrin.

Q

When is Acelyrin (NASDAQ:SLRN) reporting earnings?

A

Acelyrin’s Q2 earnings are confirmed for Monday, August 12, 2024.

Q

Is Acelyrin (SLRN) going to split?

A

There is no upcoming split for Acelyrin.

Q

What sector and industry does Acelyrin (SLRN) operate in?

A

Acelyrin is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch